Rozbor firmy
AbbVie (ABBV): after the Humira era — a new chapter for a pharmaceutical giant
Key takeaways
- Humira was the world's best-selling drug for more than a decade — AbbVie had to manage the patent cliff without a collapse.
- Skyrizi and Rinvoq are taking over in immunology and the growth trajectories of both products remain strong so far.
- AbbVie is one of the largest dividend payers in the entire sector — the company raises its dividend regularly.
- Risk lies in concentration on the immunology segment and the costly Allergan acquisition (Botox, aesthetics).
- Healthcare ETFs such as XDWH include AbbVie and provide diversification without betting on the pipeline transition.
AbbVie (ABBV) is a pharmaceutical company that had to cope with one of the greatest challenges in sector history: the end of patent protection for Humira, the world's best-selling drug. How did it manage the transition — and what does that mean for investors?
From Humira to Skyrizi and Rinvoq
Humira (adalimumab) dominated the immunology market for over a decade — rheumatoid arthritis, Crohn's disease, psoriasis. When patent protection expired in the US and Europe and biosimilars entered, analysts expected a steep revenue decline. AbbVie bet on Skyrizi (risankizumab) and Rinvoq (upadacitinib) as successors. Both drugs target similar indications with more modern mechanisms of action.
Allergan and aesthetics
The Allergan acquisition added Botox, eye drops (Restasis, Lumigan) and aesthetic medicine products to the portfolio. The aesthetics segment provides diversification beyond pure pharma but also increased the company's debt load.
Moat and risks
- Moat: strong immunology pipeline, the Allergan aesthetics platform and a historically reliable dividend.
- Pipeline risk: if Skyrizi or Rinvoq encounter a safety issue or stronger competition, the impact will be significant.
- Allergan debt: high leverage constrains the company's financial flexibility.
- Price regulation: immunology drugs are expensive — political pressure to reduce prices is persistent.
Dividend and ETF access
AbbVie is popular among dividend investors — it belongs to the group of companies that regularly raise their payout. Anyone interested in dividend aristocrats will find AbbVie a natural fit. Through XDWH or VHYL it enters a portfolio as part of a diversified basket. More in the ETF overview.
FAQ
What replaced Humira in AbbVie's portfolio?
Primarily Skyrizi (risankizumab) for immunological indications such as psoriasis and Crohn's disease, and Rinvoq (upadacitinib) for rheumatoid arthritis and other inflammatory conditions. Both drugs are growing faster than Humira is declining — so far.
Is AbbVie suitable for a dividend investor?
AbbVie regularly raises its dividend and is among the highest-yielding dividend names in the sector. Verify the specific yield — it depends on the current share price. A high dividend yield can sometimes signal that the market anticipates a dividend cut or company difficulties.
How did Allergan affect AbbVie?
The acquisition added Botox and aesthetic medicine — a more stable revenue stream less dependent on insurers. It also increased the company's debt. The net effect depends on how quickly AbbVie repays the debt and how the aesthetics segment performs.